SCNX | tickerfilter.com

Fundamental analysis

48%

Profitability 35%

Dept financing 21%

Liquidity 75%

Performance 60%

Company vs Stock growth

64.861 K 53.083 K

-11.778 K -18.16%

N/A

+ Add row to compare

Performance

5 Days

-11.23%

1 Month

-39.40%

3 Months

-82.01%

6 Months

-89.07%

1 Year

-89.07%

2 Year

-89.07%

Key data

Stock price

$0.85

P/E Ratio

5.72

DAY RANGE

$0.83 - $0.98

EPS

$17.07

52 WEEK RANGE

$0.83 - $8.19

52 WEEK CHANGE

-$89.07

MARKET CAP

51.890 M

YIELD

157.02%

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

2.80

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$316,833

AVERAGE 30 VOLUME

$5,551,909

Company detail

CEO: Surendra Ajjarapu
Region: US
Website: scienture.com
Employees: 0
IPO year: 2009

Issue type:
Market: NASDAQ
Industry: Wholesale/Wholesale – Drugs & Drug Proprietaries
Sector: Wholesale Trade

SCIENTURE HOLDINGS, Inc is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the U.S.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced the divestiture of its legacy Healthcare IT and Wholesale Operations subsidiaries Integra Pharma Solutions (IPS), Bonum H

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders. This time last year, Scienture Ho

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, LLC, a wholly owned s

SCNX - Scienture Holdings, Inc.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization